Intellipharmaceutics International Inc. (IPCI)

[cysonic]

Read the prospectus - great news here:

"As of May 24, 2017, our cash balance was $1.5 million. We currently expect to satisfy our operating cash requirements until September 2017 from cash on hand and higher quarterly profit share payments from Par Pharmaceutical, Inc. (“Par”). Should our marketing and distribution partner Mallinckrodt LLC (“Mallinckrodt”) successfully launch all or some of the strengths of our generic Seroquel XR®, then we may be cash flow positive in the third quarter of 2017."

"The Company has manufactured and shipped commercial quantities of all strengths of generic Seroquel XR® to our marketing and distribution partner Mallinckrodt."

"We expect expenditures in investing activities for the purchase of production, laboratory and computer equipment and the expansion of manufacturing and warehousing capability to be higher as we prepare for the commercialization of ANDAs, one NDA and one ANDS that are pending FDA and Health Canada approval, respectively."

"During the period commencing March 1, 2017 through May 24, 2017, 333,666 of our common shares were sold under the at-the-market offering for net proceeds to us of $773,244."


So we're on track and will NOT need to do another financing!

cysonic